PPP1R163: A Promising Drug Target for Vestibular Introduction Disorder

Target Name: VDR

NCBI ID: G7421

Content of Review Report on VDR Target / Biomarker

VDR

PPP1R163: A Promising Drug Target for Vestibular Introduction Disorder

Vestibular disorders are a group of conditions that affect the balance and coordination of the body. These disorders can range from mild to severe and can cause significant distress and impairment in daily life. One of the most common vestibular disorders is Vestibular Introduction Disorder (VDI), a condition that is characterized by episodes of vertigo (a spinning sensation) and nausea.

VDI is a serious disorder that can cause significant disability and impact quality of life. It is estimated that approximately 10% of the general population has VDI, and the condition is more common in people over the age of 50. The symptoms of VDI can vary from person to person, but some common symptoms include episodes of vertigo, nausea, vomiting, and decreased hearing.

Currently, there are no approved drugs for the treatment of VDI. The treatment options available are limited to supportive care, which includes medication for nausea and vomiting, and in some cases, hospitalization. However, these treatments can be expensive and may have significant side effects.

One of the most promising drug targets for VDI is PPP1R163, a G protein-coupled receptor (GPCR) that is located on the surface of certain cells in the inner ear. PPP1R163 is known for its role in the regulation of balance and vertigo, and scientists believe that it may be a useful target for the treatment of VDI.

PPP1R163 is a potent antagonist of the neurotransmitter GABA, which is involved in the regulation of many physiological processes in the brain. GABA is also known for its role in the regulation of balance and vertigo. By blocking GABA, PPP1R163 may be able to reduce the symptoms of VDI, such as episodes of vertigo and nausea.

In addition to its role in the regulation of GABA, PPP1R163 is also involved in the regulation of many other physiological processes in the body. For example, it is involved in the regulation of pain, anxiety, and inflammation. This suggests that PPP1R163 may have a broader range of effects than just VDI.

Scientists are currently conducting a number of studies to determine the effectiveness of PPP1R163 as a treatment for VDI. Initial studies have shown that PPP1R163 is able to reduce the symptoms of VDI, such as episodes of vertigo and nausea, in animal models of the condition. Additionally, laboratory studies have shown that PPP1R163 blocks the effects of the neurotransmitter GABA, which is involved in the regulation of many physiological processes in the brain.

While the results of these studies are promising, it is important to note that PPP1R163 is still in the early stages of development as a potential drug target for VDI. Further research is needed to determine its safety and effectiveness in human trials.

In conclusion, PPP1R163 is a promising drug target for the treatment of Vestibular Introduction Disorder. Its ability to regulate the neurotransmitter GABA and its involvement in the regulation of many other physiological processes in the body suggest that it may be a useful target for the treatment of this serious disorder. Further research is needed to determine its safety and effectiveness in human trials.

Protein Name: Vitamin D Receptor

Functions: Nuclear receptor for calcitriol, the active form of vitamin D3 which mediates the action of this vitamin on cells (PubMed:28698609, PubMed:16913708, PubMed:15728261, PubMed:10678179). Enters the nucleus upon vitamin D3 binding where it forms heterodimers with the retinoid X receptor/RXR (PubMed:28698609). The VDR-RXR heterodimers bind to specific response elements on DNA and activate the transcription of vitamin D3-responsive target genes (PubMed:28698609). Plays a central role in calcium homeostasis (By similarity). Also functions as a receptor for the secondary bile acid lithocholic acid (LCA) and its metabolites (PubMed:12016314, PubMed:32354638)

The "VDR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VDR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets